Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 25.
doi: 10.1038/s41594-025-01635-0. Online ahead of print.

Structural basis for mTORC1 regulation by the CASTOR1-GATOR2 complex

Affiliations

Structural basis for mTORC1 regulation by the CASTOR1-GATOR2 complex

Rachel M Jansen et al. Nat Struct Mol Biol. .

Abstract

Mechanistic target of rapamycin complex 1 (mTORC1) is a nutrient-responsive master regulator of metabolism. Amino acids control the recruitment and activation of mTORC1 at the lysosome through the nucleotide loading state of the heterodimeric Rag GTPases. Under low nutrients, including arginine, the GTPase-activating protein complex GATOR1 promotes GTP hydrolysis on RagA/B, inactivating mTORC1. GATOR1 is regulated by the cage-like GATOR2 complex and cytosolic amino acid sensors. To understand how the arginine sensor CASTOR1 binds to GATOR2 to disinhibit GATOR1 under low cytosolic arginine, we determined the cryo-electron microscopy structure of human GATOR2 bound to CASTOR1 in the absence of arginine. Two MIOS WD40 domain β-propellers of the GATOR2 cage engage with both subunits of a single CASTOR1 homodimer. Each propeller binds to a negatively charged MIOS-binding interface on CASTOR1 that is distal to the arginine pocket. The structure shows how arginine-triggered loop ordering in CASTOR1 blocks the MIOS-binding interface, switches off its binding to GATOR2 and, thus, communicates to downstream mTORC1 activation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: J.H.H. is a cofounder and shareholder of Casma Therapeutics, receives research funding from Hoffmann-La Roche and has consulted for Corsalex. R.Z. is a cofounder and shareholder of Frontier Medicines and a science advisory board member for Nine Square Therapeutics and receives research funding from Genentech. The other authors declare no competing interests.

Update of

Similar articles

References

    1. Ballabio, A. & Bonifacino, J. S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol. 21, 101–118 (2020). - PubMed
    1. Goul, C., Peruzzo, R. & Zoncu, R. The molecular basis of nutrient sensing and signalling by mTORC1 in metabolism regulation and disease. Nat. Rev. Mol. Cell Biol. 24, 857–875 (2023). - PubMed
    1. Condon, K. J. & Sabatini, D. M.Nutrient regulation of mTORC1 at a glance. J. Cell Sci. 132, jcs222570 (2019). - PubMed - PMC
    1. Battaglioni, S., Benjamin, D., Walchli, M., Maier, T. & Hall, M. N. mTOR substrate phosphorylation in growth control. Cell 185, 1814–1836 (2022). - PubMed
    1. Chiarini, F., Evangelisti, C., McCubrey, J. A. & Martelli, A. M. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol. Sci. 36, 124–135 (2015). - PubMed

LinkOut - more resources